Rockwell Medical Analyst Ratings
Rockwell Medical Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/04/2023 | 436.59% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 09/28/2023 | 436.59% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 08/15/2023 | 436.59% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 07/17/2023 | 436.59% | HC Wainwright & Co. | $9 → $11 | Maintains | Buy |
| 05/30/2023 | 339.02% | HC Wainwright & Co. | $7 → $9 | Maintains | Buy |
| 05/02/2023 | 241.46% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 04/04/2023 | 241.46% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 02/13/2023 | 241.46% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 02/08/2023 | 241.46% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 08/30/2022 | 290.24% | HC Wainwright & Co. | $3 → $8 | Maintains | Buy |
| 01/18/2022 | 46.34% | HC Wainwright & Co. | $5 → $3 | Maintains | Buy |
| 09/07/2021 | 143.9% | HC Wainwright & Co. | $5.5 → $5 | Maintains | Buy |
| 02/08/2021 | 168.29% | HC Wainwright & Co. | $9 → $5.5 | Maintains | Buy |
| 04/07/2020 | 339.02% | HC Wainwright & Co. | $11 → $9 | Maintains | Buy |
| 11/12/2019 | 192.68% | Piper Sandler | $10 → $6 | Maintains | Overweight |
| 06/25/2019 | 436.59% | Cantor Fitzgerald | → $11 | Initiates Coverage On | → Overweight |
| 06/24/2019 | 387.8% | Piper Sandler | → $10 | Initiates Coverage On | → Overweight |
| 10/19/2018 | 436.59% | IFS Securities | → $11 | Downgrades | Strong Buy → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/04/2023 | 436.59% | HC Wainwright公司 | →$11 | 重申 | 購買→購買 |
| 09/28/2023 | 436.59% | HC Wainwright公司 | →$11 | 重申 | 購買→購買 |
| 2023年08月15日 | 436.59% | HC Wainwright公司 | →$11 | 重申 | 購買→購買 |
| 07/17/2023 | 436.59% | HC Wainwright公司 | $9→$11 | 維護 | 買 |
| 2023年05月30日 | 339.02% | HC Wainwright公司 | $7→$9 | 維護 | 買 |
| 05/02/2023 | 241.46% | HC Wainwright公司 | →$7 | 重申 | →購買 |
| 04/04/2023 | 241.46% | HC Wainwright公司 | →$7 | 重申 | →購買 |
| 02/13/2023 | 241.46% | HC Wainwright公司 | →$7 | 重申 | →購買 |
| 02/08/2023 | 241.46% | HC Wainwright公司 | $8→$7 | 維護 | 買 |
| 2022年08月30日 | 290.24% | HC Wainwright公司 | $3→$8 | 維護 | 買 |
| 01/18/2022 | 46.34% | HC Wainwright公司 | $5→$3 | 維護 | 買 |
| 09/07/2021 | 143.9% | HC Wainwright公司 | $5.5→$5 | 維護 | 買 |
| 02/08/2021 | 168.29% | HC Wainwright公司 | $9→$5.5 | 維護 | 買 |
| 04/07/2020 | 339.02% | HC Wainwright公司 | $11→$9 | 維護 | 買 |
| 2019年11月12日 | 192.68% | 派珀·桑德勒 | $10→$6 | 維護 | 超重 |
| 2019年06月25日 | 436.59% | 康託·菲茨傑拉德 | →$11 | 開始承保 | →超重 |
| 2019年06月24日 | 387.8% | 派珀·桑德勒 | →$10 | 開始承保 | →超重 |
| 2018年10月19日 | 436.59% | IFS證券 | →$11 | 評級下調 | 強勢買入→跑贏大盤 |
What is the target price for Rockwell Medical (RMTI)?
羅克韋爾醫療公司(RMTI)的目標價格是多少？
The latest price target for Rockwell Medical (NASDAQ: RMTI) was reported by HC Wainwright & Co. on October 4, 2023. The analyst firm set a price target for $11.00 expecting RMTI to rise to within 12 months (a possible 436.59% upside). 9 analyst firms have reported ratings in the last year.
羅克韋爾醫療公司(納斯達克代碼：RMTI)的最新目標價是由HC Wainwright&Co.於2023年10月4日報道的。這家分析公司將目標價定為11美元，預計RMTI將在12個月內升至(可能上漲436.59%)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Rockwell Medical (RMTI)?
羅克韋爾醫療公司(RMTI)最近的分析師評級是多少？
The latest analyst rating for Rockwell Medical (NASDAQ: RMTI) was provided by HC Wainwright & Co., and Rockwell Medical reiterated their buy rating.
羅克韋爾醫療公司(納斯達克代碼：RMTI)的最新分析師評級由HC Wainwright&Co.提供，羅克韋爾醫療公司重申其買入評級。
When is the next analyst rating going to be posted or updated for Rockwell Medical (RMTI)?
羅克韋爾醫療公司(RMTI)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rockwell Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rockwell Medical was filed on October 4, 2023 so you should expect the next rating to be made available sometime around October 4, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與羅克韋爾醫療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。羅克韋爾醫療公司的上一次評級是在2023年10月4日提交的，所以你應該預計下一次評級將在2024年10月4日左右的某個時候公佈。
Is the Analyst Rating Rockwell Medical (RMTI) correct?
分析師對羅克韋爾醫療公司(RMTI)的評級正確嗎？
While ratings are subjective and will change, the latest Rockwell Medical (RMTI) rating was a reiterated with a price target of $0.00 to $11.00. The current price Rockwell Medical (RMTI) is trading at is $2.05, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但羅克韋爾醫療公司(RMTI)的最新評級被重申，目標價在0.00美元至11.00美元之間。羅克韋爾醫療(RMTI)目前的交易價格為2.05美元，在分析師的預測範圍內。